Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma

BACKGROUND: Ipilimumab is an approved immunotherapy that has shown an overall survival benefit in patients with cutaneous metastatic melanoma in two phase III trials. As results of registrational trials might not answer all questions regarding safety and efficacy of ipilimumab in patients with advan...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:J Transl Med
Hauptverfasser: Zimmer, Lisa, Eigentler, Thomas K., Kiecker, Felix, Simon, Jan, Utikal, Jochen, Mohr, Peter, Berking, Carola, Kämpgen, Eckhart, Dippel, Edgar, Stadler, Rudolf, Hauschild, Axel, Fluck, Michael, Terheyden, Patrick, Rompel, Rainer, Loquai, Carmen, Assi, Zeinab, Garbe, Claus, Schadendorf, Dirk
Format: Artigo
Sprache:Inglês
Veröffentlicht: BioMed Central 2015
Schlagworte:
Research
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4635983/
https://ncbi.nlm.nih.gov/pubmed/26541511
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12967-015-0716-5
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge